<DOC>
	<DOCNO>NCT00993239</DOCNO>
	<brief_summary>A Phase 1 open-label , non-randomized dose escalation study determine maximum tolerate dose ( MTD ) characterize safety tolerability Birinapant ( TL32711 ) .</brief_summary>
	<brief_title>Dose Escalation Safety Study TL32711 Adults With Refractory Solid Tumors Lymphoma</brief_title>
	<detailed_description>The purpose Phase 1 open-label , non-randomized dose escalation study determine maximum tolerate dose ( MTD ) characterize safety tolerability Birinapant ( TL32711 ) administer 30 minute intravenous infusion weekly three week per repeat 4 week interval subject refractory solid tumor lymphoma . Additionally study assess anti-tumor activity , pharmacokinetics , exploratory biomarkers measurement pharmacodynamic effect .</detailed_description>
	<criteria>Key Advanced metastatic unresectable malignancy refractory currently available standard therapy effective therapy exists . The subject 's malignancy must confirm prior pathologic study . Evaluable disease ( measurable nonmeasurable ) Response Evaluation Criteria Solid Tumors ( RECIST , Version 1.1 ) Revised Response Criteria Malignant Lymphoma ( RRCML ) ( Cheson 2007 ) . Life expectancy great 3 month . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Adequate renal function , define serum creatinine ≤ 1.5 X upper limit normal ( ULN ) , calculate creatinine clearance ≥ 60 ml/min . Adequate hepatic function , define aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) level ≤ 3 X ULN total bilirubin &lt; 1.5 X ULN . Adequate bone marrow function , define absolute neutrophil ( ANC ) ≥ 1,500/mm3 ( ≥1.5 X106/L ) , platelet count ≥ 75,000/mm3 ( ≥ 75 X106/L ) , hemoglobin ≥ 10 mg/dL absence transfusion . Key Recent anticancer treatment define : Standard investigational anticancer therapy within 4 week prior first dose TL32711 . Exception : continued hormonal intervention sensitive disease . Radiation therapy within 2 week prior first dose TL32711 . Clinically significant pulmonary illness result Grade ≥ 2 hypoxia ( National Cancer Institute Common Terminology criterion Adverse Events [ NCI CTCAE , v4 ] ) requirement supplemental oxygen , pulse oximetry le 90 % saturation room air . Symptomatic uncontrolled brain metastasis require current treatment ( le 4 week last cranial radiation 2 week last steroid ) . Impaired cardiac function clinically significant cardiac disease . Ongoing autoimmune disease history autoimmune disease within past 5 year . Autoimmune disease include limited systemic lupus erythematosis , scleroderma , rheumatoid arthritis , psoriasis , psoriatic arthritis , ulcerative colitis regional enteritis ( Crohn 's disease ) . Systemic chronic topical corticosteroid immunosuppressive therapy within 4 week prior study entry anticipate need systemic corticosteroid immunosuppressive therapy study participation . Skin lesion Grade ≥ 2 severity ( NCI CTCAE v4 ) , except alopecia . Lack recovery prior adverse event Grade ≤1 severity ( NCI CTCAE v 4 ) ( except alopecia neuropathy ) due medication administer prior first dose TL32711 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>